Tenaya Therapeutics Inc
TNYA1.320USD
+0.100+8.20%
Fechamento 09/18, 16:00（ET）Cotações atrasadas em 15 min
215.13MValor de mercado
PerdaP/L TTM
Mais detalhes de Tenaya Therapeutics Inc Empresa
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Informações da empresa
Código da empresaTNYA
Nome da EmpresaTenaya Therapeutics Inc
Data de listagemJul 30, 2021
CEOMr. Faraz Ali
Número de funcionários97
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 30
Endereço171 Oyster Point Blvd., Suite 500
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94080
Telefone14158652066
Sitehttps://www.tenayatherapeutics.com/
Código da empresaTNYA
Data de listagemJul 30, 2021
CEOMr. Faraz Ali
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
82.91K
-14.91%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. David V. Goeddel, Ph.D.
Dr. David V. Goeddel, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey T. (Jeff) Walsh
Mr. Jeffrey T. (Jeff) Walsh
Independent Director
Independent Director
--
--
Dr. Deepak Srivastava, M.D.
Dr. Deepak Srivastava, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
82.91K
-14.91%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 23 de ago
Atualizado em: sáb, 23 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Column Group LP
5.77%
The Vanguard Group, Inc.
2.92%
Empery Asset Management, L.P.
2.89%
BlackRock Institutional Trust Company, N.A.
1.64%
Renaissance Technologies LLC
1.13%
Outro
85.66%
Investidores
Investidores
Proporção
The Column Group LP
5.77%
The Vanguard Group, Inc.
2.92%
Empery Asset Management, L.P.
2.89%
BlackRock Institutional Trust Company, N.A.
1.64%
Renaissance Technologies LLC
1.13%
Outro
85.66%
Tipos de investidores
Investidores
Proporção
Investment Advisor
6.64%
Venture Capital
6.33%
Investment Advisor/Hedge Fund
5.83%
Hedge Fund
2.39%
Individual Investor
0.70%
Research Firm
0.55%
Private Equity
0.28%
Family Office
0.18%
Outro
77.09%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
235
93.48M
57.36%
+20.23M
2025Q1
240
59.62M
37.68%
-6.11M
2024Q4
227
46.66M
58.78%
-21.29M
2024Q3
228
59.37M
75.30%
-7.13M
2024Q2
219
58.72M
74.83%
-7.58M
2024Q1
206
57.55M
73.35%
-12.34M
2023Q4
191
47.88M
70.30%
-10.62M
2023Q3
197
52.92M
79.61%
-6.27M
2023Q2
192
50.82M
77.84%
-5.65M
2023Q1
177
48.22M
74.02%
-17.43M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Column Group LP
49.31M
30.32%
+39.91M
+424.60%
May 07, 2025
The Vanguard Group, Inc.
4.08M
2.51%
+809.99K
+24.75%
Mar 31, 2025
Empery Asset Management, L.P.
8.73M
5.37%
+8.73M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
3.05%
-52.13K
-1.04%
Mar 31, 2025
Renaissance Technologies LLC
1.54M
0.95%
+1.54M
--
Mar 31, 2025
AQR Capital Management, LLC
775.66K
0.48%
+775.66K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.38M
0.85%
+106.44K
+8.39%
Mar 31, 2025
Euclidean Capital, L.L.C.
1.02M
0.62%
--
--
Mar 31, 2025
Alphabet, Inc.
915.71K
0.56%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
